Bottom line
LYFAX vs MEDI: the short answer
LYFAX (AlphaCentric Life Sciences and Healthcare Fund) and MEDI (Harbor Health Care ETF) are both mutual funds.
MEDI is cheaper at 0.8% vs 1.66% — a difference of $86 a year per $10,000 invested.
Over one year, MEDI returned +27.1% vs +20.6% for LYFAX.
LYFAX has a front-end sales load of up to 5.75%; the other does not.
Updated Nov 19, 2026
LYFAX vs MEDI side by side
| LYFAX | MEDI | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Mutual | Oakmark (Harris) |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.66% | 0.8% |
| Annual cost per $10k | $166 | $80 |
| 10-yr cost on $10k (prospectus) | $3,039 | $990 |
| Max front load | 5.75% | None |
| 12b-1 fee | 0.25% | 0% |
| 1-yr return | +20.6% | +27.1% |
| 5-yr return (annualized) | +4.1% | — |
| 10-yr return (annualized) | — | — |
| Best quarter | +27.5% | +14.4% |
| Worst quarter | −11.9% | −10.9% |
| Net assets (fund) | $46.6M | $41.2M |
| Number of holdings | 62 | 44 |
| Portfolio turnover | 107% | 167% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | LYFAX | MEDI | Difference |
|---|---|---|---|
| 2025 | +27.9% | +27.1% | +0.8% |
| 2024 | −0.4% | +0.5% | −1.0% |
| 2023 | +6.9% | +24.8% | −17.9% |
Source: Fund prospectus bar charts
Holdings overlap
6 of LYFAX's top 25 holdings also appear in MEDI's top 25.
| Holding | LYFAX | MEDI |
|---|---|---|
| Gilead Sciences Inc | 5.53% | 5.10% |
| Vertex Pharmaceuticals Inc | 5.33% | 1.22% |
| Argenx Se | 3.59% | 2.07% |
| Insmed Inc | 2.60% | 2.52% |
| Rhythm Pharmaceuticals Inc | 2.25% | 4.02% |
| Abbvie Inc | 1.95% | 3.09% |
Source: SEC Form N-PORT
LYFAX top 10
- Gilead Sciences Inc — 5.53%
- Vertex Pharmaceuticals Inc — 5.33%
- Astrazeneca Plc — 4.63%
- First American Funds Inc — 4.26%
- Roivant Sciences Ltd — 3.67%
- Argenx Se — 3.59%
- Neurocrine Biosciences Inc — 3.51%
- Incyte Corp — 3.51%
- Axsome Therapeutics Inc — 3.43%
- Apogee Therapeutics Inc — 3.28%
MEDI top 10
- Eli Lilly & Co — 20.78%
- Ascendis Pharma A/S — 13.61%
- Gilead Sciences Inc — 5.10%
- Rhythm Pharmaceuticals Inc — 4.02%
- AbbVie Inc — 3.09%
- Intuitive Surgical Inc — 2.83%
- Cencora Inc — 2.75%
- Revolution Medicines Inc — 2.54%
- Insmed Inc — 2.52%
- Merck & Co Inc — 2.47%
FAQ
What is the difference between LYFAX and MEDI?
Which is cheaper, LYFAX or MEDI?
Should I own both LYFAX and MEDI?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.